Craig T Wallington-Beddoe

List of Publications by Year
in descending order

33	802	623188 14	552369 26
papers	citations	h-index	g-index

35	35	35	1409
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Desmogleinâ€2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 2022, 16, 1221-1240.	2.1	9
2	Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. Neoplasia, 2022, 24, 1-11.	2.3	12
3	Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood, 2022, 139, 3737-3751.	0.6	20
4	Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells. ACS Pharmacology and Translational Science, 2021, 4, 713-729.	2.5	5
5	Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma. ACS Pharmacology and Translational Science, 2021, 4, 1050-1065.	2.5	11
6	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16â€02 trial. British Journal of Haematology, 2021, 194, 580-586.	1.2	5
7	Prognostic and predictive biomarker developments in multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 151.	6.9	49
8	Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma. Resistance To Targeted Anti-cancer Therapeutics, 2021, , 39-59.	0.1	1
9	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	6.3	188
10	Resistance Mechanisms to Novel Therapies in Myeloma. , 2019, , .		3
11	INHIBITION OF SPHINGOSINE KINASE 2 RESENSITISES BORTEZOMIB-RESISTANT MULTIPLE MYELOMA. Experimental Hematology, 2019, 76, S58.	0.2	0
12	CERAMIDE EVOKES AN APOPTOTIC INTEGRATED STRESS RESPONSE IN ACUTE MYELOID LEUKEMIA. Experimental Hematology, 2019, 76, S83.	0.2	0
13	Sphingolipids and the unfolded protein response. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 1483-1494.	1.2	20
14	Identification of sphingosine kinase 1 as a therapeutic target in Bâ€lineage acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 184, 443-447.	1.2	11
15	Resistance to proteasome inhibitors and other targeted therapies in myeloma. British Journal of Haematology, 2018, 182, 11-28.	1.2	78
16	Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies. Cell Death Discovery, 2018, 4, 72.	2.0	50
17	Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. Biomarker Research, 2018, 6, 6.	2.8	4
18	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood, 2017, 129, 771-782.	0.6	67

#	Article	IF	Citations
19	Targeting sphingosine kinase 1 in acute myeloid leukemia: translation to clinic. International Journal of Hematologic Oncology, 2017, 6, 31-34.	0.7	5
20	Enhancing ER stress in myeloma. Aging, 2017, 9, 1645-1646.	1.4	5
21	Novel therapies for multiple myeloma. Aging, 2017, 9, 1857-1858.	1.4	6
22	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 2017, 8, 43602-43616.	0.8	37
23	Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing MYC Expression. Cancer Research, 2014, 74, 2803-2815.	0.4	73
24	Targeting sphingosine kinase 2 suppresses MYC expression and kills acute lymphoblastic leukemia cells. Experimental Hematology, 2013, 41, S49.	0.2	0
25	Oncogenic properties of sphingosine kinases in haematological malignancies. British Journal of Haematology, 2013, 161, 623-638.	1.2	17
26	Evaluation Of Sphingosine Kinase 1 As a Therapeutic Target In B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1426-1426.	0.6	0
27	Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia. PLoS ONE, 2012, 7, e36429.	1.1	22
28	Identification of Sphingosine Kinases As Therapeutic Targets in B-Lineage Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1499-1499.	0.6	2
29	FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy, 2011, 7, 707-715.	4.3	68
30	Sphingosine Kinase Inhibition Has Pre-Clinical Activity in Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3573-3573.	0.6	0
31	FTY720 Has Potent Anti-Leukemic Effects on Acute Lymphoblastic Leukemia Cells and Results In Caspase Independent Cell Death. Blood, 2010, 116, 3260-3260.	0.6	0
32	Failure to Achieve a Threshold Dose of CD34+CD110+ Progenitor Cells in the Graft Predicts Delayed Platelet Engraftment after Autologous Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2009, 15, 1386-1393.	2.0	17
33	Effectiveness of interferon alfaâ€2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Medical Journal of Australia, 2003, 178, 267-271.	0.8	17